Xeljanz/Xeljanz XR Approved for Active Ankylosing Spondylitis
The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.
Diagnosis & Disease Information
Rinvoq Labeling Updated to Include Class Warnings Related to JAK Inhibitors
The update follows the FDA’s Drug Safety Communication, which was based on a completed review of a large randomized safety clinical trial evaluating tofacitinib in patients with rheumatoid arthritis.
PRP Injections Do Not Ease Pain in Knee Osteoarthritis
No difference seen in change in median tibial cartilage volume at 12 months for platelet-rich plasma versus saline placebo injections
Guselkumab Improves Psoriatic Arthritis in Patients With Inadequate Response to TNFi
The phase 3 COSMOS study evaluated the efficacy and safety of guselkumab in 285 adults with active PsA who had an inadequate response to anti-tumor necrosis factors.
Most Immunosuppressive Meds Not Tied to Worse COVID-19 Outcomes
Except for rituximab, no increased risk seen for in-hospital death or mechanical ventilation for those on long-term immunosuppressive therapy
Flare Risk Reduced With Secukinumab in 2 Types of Juvenile Idiopathic Arthritis
Findings showed that treatment with secukinumab resulted in a 72% reduction in the risk of flare at week 104 compared with placebo.
Steroid Injection No Better for Long-Term Carpal Tunnel Symptoms
At five years, no difference seen in symptoms, but rates of subsequent surgical treatment lower with methylprednisolone versus saline injection
MPR Weekly Dose Podcast Episode 97
This week: The FDA authorize boosters for Moderna and Janssen and okay ‘mixing and matching’ of vaccines for the booster dose. The first interchangeable biosimilar to Humira is approved. Also there’s approvals in dry eye disease, pain management and opioid overdoses.
First Interchangeable Biosimilar to Humira Gets FDA Approval
The interchangeable biosimilar product may be substituted for the reference product by a pharmacist.
Data Support Upadacitinib in Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis
No new safety risks were identified in the studies.
